Zepbound and gastroparesis: how common it is and how to avoid it

Zepbound (tirzepatide) is not known to directly cause gastroparesis (sometimes called Zepbound stomach paralysis), but the medication does slow stomach emptying. People taking Zepbound for weight loss, or considering it, may come across Zepbound reviews that mention it. Nausea, diarrhea, constipation, and vomiting are among the more common side effects.

Reading about stomach paralysis can be worrying. Gastroparesis is not considered a common side effect of Zepbound, but cases of impaired stomach emptying with gastroparesis-like symptoms have been reported among those taking Zepbound. Research on the topic is limited, and other factors may be involved.

Zepbound is not known to directly cause gastroparesis, a condition in which the stomach empties too slowly even though nothing is blocking it. However, its effect on digestion is still relevant. Zepbound delays gastric emptying — the movement of food from the stomach to the small intestine — which is also seen in people with gastroparesis. Some research on GLP-1 medications such as  Wegovy (semaglutide) has raised questions about whether this delay could contribute to gastroparesis in some people, but the evidence so far is limited. Given its effects on gastric emptying and limited data on the use of Zepbound in people with gastroparesis, Zepbound’s prescribing information specifically says it isn’t recommended for people who have severe gastroparesis.   

Food normally moves out of the stomach gradually. Research suggests that GLP-1s such as Zepbound (a dual GLP-1/GIP medication) slow this process, which is part of how Zepbound works for weight loss. Food that stays in the stomach longer may help people feel full longer and eat less, which may contribute to weight loss.

With gastroparesis, the delay is caused by a problem with the stomach muscles and the nerves that control them, not by a blockage. Normally, the stomach muscles squeeze in pulses to break down food and move it into the small intestine. In gastroparesis, the muscles and nerves do not work as reliably, so food stays in the stomach longer than it should.

The link between gastroparesis and Zepbound may also be one of correlation, not causation. Many people taking GLP-1s have diabetes, which increases the risk of gastroparesis. Obesity is also a risk factor. Gastroparesis is uncommon in the general population: a study of electronic medical records in the United States found it in about 0.2% of people overall, compared with about 1.3% of people with type 2 diabetes and 4.6% of people with type 1 diabetes.

It is not yet clear how common gastroparesis is with Zepbound or GLP-1s in general. Research so far suggests that it is rare.

One analysis of US insurance claims for adults with type 2 diabetes found that severe stomach and intestinal problems requiring emergency or hospital care were uncommon with tirzepatide and occurred at rates similar to those with semaglutide and dulaglutide. Notably, all three medications were linked to a higher risk of these problems than a different type of diabetes medication called SGLT-2 inhibitors, which includes Jardiance (empagliflozin) and Farxiga (dapagliflozin). Because the study grouped gastroparesis with other conditions, such as bowel obstruction, severe constipation, and acute pancreatitis, it is not possible to tell how many people developed gastroparesis specifically.

A systematic review of 12 case reports found that 11 of the 13 people who developed gastroparesis while taking GLP-1s had type 2 diabetes. None of these people were taking tirzepatide specifically. Because the review included only a small number of patients overall, it cannot show whether diabetes raises the risk.

A third analysis of 55 clinical trials found no increased risk of gastroparesis with GLP-1s, but did find an increased risk of heartburn and gallstones.

See if you qualify

Symptoms of Zepbound gastroparesis 

Symptoms of gastroparesis may be similar whether or not a person is taking Zepbound. Common symptoms include:

• Nausea

• Vomiting

• Bloating

• Feeling full quickly

• Feeling full long after eating

• Low appetite

• Stomach pain

• Burping

• Heartburn

Gastroparesis is usually diagnosed when someone has ongoing symptoms (often for at least three months) and a test shows that their stomach empties too slowly. Depending on your symptoms, a healthcare provider may also check to make sure there is nothing blocking the stomach. 

Zepbound is not recommended for people with severe gastroparesis. Zepbound delays gastric emptying, which may contribute to both its weight loss effect and some uncomfortable GI side effects, such as constipation, nausea and vomiting. Whether this delay raises the risk of gastroparesis itself is not yet clear.

Poorly controlled diabetes may also contribute to gastroparesis, since high blood sugar can damage the nerves of the digestive tract. Keeping blood sugar well controlled is an important part of managing and even preventing gastroparesis in people with diabetes, which GLP1 medications may be able to help with. Tirzepatide is also approved under the brand name Mounjaro for type 2 diabetes.

Other conditions linked to gastroparesis include:

• Underactive thyroid (hypothyroidism)

• Surgery on the upper digestive tract or chest

• Certain autoimmune diseases

• Nervous system disorders, such as multiple sclerosis or Parkinson's disease

• Certain viral infections

Who is most at risk for gastroparesis on Zepbound?

Some people may have higher risk of gastroparesis, and it is not yet known whether these factors also raise the risk on Zepbound. People who may be at higher risk include those who:

• Have diabetes

• Have obesity

• Take other medications that can delay gastric emptying, such as opioids

• Use cannabis, which can slow gastric emptying

• Have had surgery on the esophagus, stomach, or small intestine

• Have a neurological or autoimmune condition that affects digestion

Gastroparesis is uncommon overall, but a US study found it was more common among people with diabetes. A healthcare provider can help with questions about individual risk.

There is no proven way to prevent gastroparesis on Zepbound, but sharing health information is an important first step. Before starting Zepbound, tell your healthcare provider about any medications and health conditions, such as diabetes or pre-existing digestive problems, so they can assess whether Zepbound is appropriate and plan accordingly.

Other steps that may help reduce GI side effects on Zepbound include:

• Follow the prescribed dosage schedule. Take Zepbound only as prescribed, and do not increase the dose unless a healthcare provider says to. Zepbound follows a gradual dosage titration schedule to limit side effects, including serious gastrointestinal reactions.

• Take doses on schedule. Zepbound is designed to be taken once weekly. If a dose is missed, the prescribing information says to take it as soon as possible within four days (96 hours); after four days, skip it and take the next dose on the regular day. If multiple doses of medication are missed, contact a healthcare provider since the dose may need to be adjusted.

• Adjust eating habits. Eating smaller portions more frequently throughout the day may help limit nausea and vomiting. Staying hydrated by drinking water in small sips rather than large gulps may help prevent nausea. Eating when hungry, stopping when full, and choosing low-fat, Zepbound-friendly foods may help avoid upsetting the stomach.

• Monitor symptoms. Note how long symptoms last and when they are worst — for many people, the days after an injection. Keeping a symptom diary may help. Contact a healthcare provider about any new, persistent, or worsening symptoms.

• Speak up if symptoms are severe. Contact a healthcare provider and don’t hesitate to seek emergency medical care if you are experiencing  severe or persistent stomach pain, nausea, diarrhea, vomiting, or signs of dehydration, such as dizziness or dark urine. 

Slower stomach emptying is an expected effect of Zepbound, while gastroparesis is not. These questions can help distinguish typical side effects from possible warning signs of stomach paralysis, but only a healthcare provider can diagnose gastroparesis:

Can you eat a meal, even if it’s a small one? 

People with gastroparesis may feel full after just a few bites of food or be unable to keep food down at all. With Zepbound, a person may feel full much sooner than before but typically can still eat a meal.

Are your symptoms typically worse after you inject Zepbound? 

Zepbound and gastroparesis can both cause nausea, vomiting, bloating, stomach pain, burping, and heartburn. With Zepbound, these symptoms may feel most intense in the days following an injection and often fade with time. Gastroparesis, by contrast, is a longer-lasting condition. It is generally diagnosed when symptoms have lasted at least three months and testing shows the stomach is emptying too slowly in the absence of a blockage.

Have your GI symptoms stayed persistent, even after months of taking Zepbound? 

Research on long-acting GLP-1s suggests the slowing of gastric emptying lessens with continued use, and for tirzepatide the effect diminishes over time. 

According to the Zepbound prescribing information, nausea, vomiting, and diarrhea mostly occur during dose escalation and decrease over time, so symptoms may be more noticeable when starting a GLP-1 injection or increasing the dose. Symptoms that persist after months of treatment may be worth discussing with a healthcare provider.

Seek emergency medical attention for severe or ongoing vomiting, difficulty keeping any food down, severe stomach pain, or signs of dehydration.

A healthcare provider can address any concerns about the risk of stomach paralysis on Zepbound.

Contact a healthcare provider if gastroparesis on Zepbound is suspected or if any of the following symptoms occur:

• You feel full soon after you start eating, and your appetite stays low for a long time afterward.

• You have significant nausea, vomiting, bloating, belching, or stomach pain — even after a few weeks of taking Zepbound.

• You have signs of dehydration, such as reduced urination, dark urine, fatigue, lightheadedness, thirst, or dry mouth.

• You feel dizzy or fatigued on Zepbound.

If you are experiencing severe symptoms, don’t hesitate to seek emergency medical attention.

Check for free

Zepbound is generally well tolerated if taken appropriately and as prescribed. Slower stomach emptying is an expected effect of Zepbound, while gastroparesis is not. Gastroparesis appears to be rare on Zepbound, and research has not shown clearly whether the medication raises the risk. The main points:

• Risk factors for gastroparesis in general include diabetes, obesity, previous stomach or intestinal surgery, and certain autoimmune or nervous system conditions, and are worth discussing with a healthcare provider before starting Zepbound.

• The delay in gastric emptying with Zepbound tends to be greatest after the first dose and often lessens over time, while gastroparesis is a longer-lasting condition diagnosed after symptoms have lasted for at least three months and testing shows evidence of slow stomach emptying. 

• Following the prescribed dosage schedule, sharing a full medical history, and tracking symptoms may help problems get recognized earlier.

• Severe, persistent, or worsening symptoms warrant contacting a healthcare provider.